Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401
MT newswire2026/10/08 18:2502:25 PM EDT, 10/08/2026 (MT Newswires) -- (Updates with the stock move in the headline and first paragraph and the Wells Fargo upgrade in the last.) Editas Medicine (EDIT) shares rose 3.1% in Thursday trading after the company received approval in Australia to initiate the phase 1/2 clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia. The trial won approval from Australia's Human Research Ethics Committee and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration, Editas said. The study has also been submitted for review in New Zealand, and if approved, patients in both countries will be eligible to enroll, the company said. Editas said new preclinical data demonstrating durability of LDL-C reduction with EDIT-401 will be released at the American Heart Association Scientific Sessions from Nov. 6 to Nov. 9. Wells Fargo upgraded Editas to overweight from equal weight with a $6 price target. Price: 2.84, Change: +0.09, Percent Change: +3.09
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF
Crypto prices
More
